| ID Source | ID |
|---|---|
| PubMed CID | 54682045 |
| MeSH ID | M0069124 |
| Synonym |
|---|
| tegunor |
| ((1,2-ethanediylbis(carbamodithioato))(2-))manganese, mixt. with ((1,2-ethanediylbis(carbamodithioato))(2-))zinc & 2(or 4)-isooctyl-4,6(or 2,6)-dinitrophenyl 2-buten oate |
| ethanaminium, 2-hydroxy-n,n,n-trimethyl-, salt with 2-hydroxybenzoic acid (1:1), mixt. with 2-hydroxybenzoic acid magnesium salt (2:1) |
| choline magnesium trisalicylate |
| DB01401 |
| tricosal (tn) |
| D07694 |
| 64425-90-7 |
| unii-djj95fjp1h |
| choline magnesium salicylate |
| nsc 751675 |
| tricolsal |
| djj95fjp1h , |
| trisalicylate-choline |
| choline magnesium trisalicylate [who-dd] |
| ethanaminium, 2-hydroxy-n,n,n-trimethyl-, 2-hydroxybenzoate (1:1), mixt. with (t-4)-bis(2-(hydroxy-.kappa.o)benzoato-.kappa.o)magnesium |
| FQCQGOZEWWPOKI-UHFFFAOYSA-K |
| cholinemagnesiumtrisalicylate |
| Q20817211 |
| DTXSID901344133 |
Choline magnesium trisalicylate is a non-acetylated salicylates used widely as a nonsteroidal anti-inflammatory drug.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Choline magnesium trisalicylate is a non-acetylated salicylate used widely as a nonsteroidal anti-inflammatory drug. " | ( Eosinophilic hepatitis after ingestion of choline magnesium trisalicylate. Nadkarni, MM; Peller, CA; Retig, J, 1992) | 1.99 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Salicylate levels were not sustained between doses and elimination rates and half-life were similar for both preparations." | ( A pharmacokinetic comparison of choline magnesium trisalicylate and soluble aspirin. Berry, D; Gibson, T; Helliwell, M; Volans, G, 1984) | 0.55 |
Claims that twice-daily dosage of choline magnesium trisalicylate (CMT) may alter salicylates disposal kinetics and result in sustained plasma levels were examined. 18 healthy volunteers were administered single doses of commercially available solid dosage forms of aspirin, magnesium salicyllate (I), and choline magridate (II)
| Excerpt | Relevance | Reference |
|---|---|---|
| " These data show that NSAIDs can affect the disposition of methotrexate, possibly increasing the potential for toxicity and necessitating dosage adjustments." | ( The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Bradley, JD; Brater, DC; Hall, SD; Jones, DR; Krohn, K; Tracy, TS, 1992) | 0.28 |
| " The 24-h area under the salicylate curve (AUC0-24 h) after the final 3000-mg salicylate dose averaged about twice the mean 12-h AUC after the last 1500-mg dose, indicating that the two dosing regimens were equally bioavailable." | ( Choline magnesium trisalicylate: comparative pharmacokinetic study of once-daily and twice-daily dosages. Kann, J; Levitt, MJ, 1984) | 1.71 |
| "Claims that twice-daily dosage of choline magnesium trisalicylate (CMT) may alter salicylate disposal kinetics and result in sustained plasma levels were examined." | ( A pharmacokinetic comparison of choline magnesium trisalicylate and soluble aspirin. Berry, D; Gibson, T; Helliwell, M; Volans, G, 1984) | 0.83 |
| "Eighteen healthy volunteers were administered single doses of commercially available solid dosage forms of aspirin, magnesium salicylate (I), and choline magnesium trisalicylate (II), equivalent to approximately 500 mg of salicylic acid, in a randomized, complete crossover design." | ( Comparative plasma salicylate and urine salicylurate levels following administration of aspirin, magnesium salicylate, and choline magnesium trisalicylate. Mason, WD, 1980) | 0.67 |
| Pathway | Proteins | Compounds |
|---|---|---|
| Trisalicylate-Choline Action Pathway | 29 | 67 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 23 (67.65) | 18.7374 |
| 1990's | 8 (23.53) | 18.2507 |
| 2000's | 2 (5.88) | 29.6817 |
| 2010's | 1 (2.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.07) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 17 (48.57%) | 5.53% |
| Reviews | 1 (2.86%) | 6.00% |
| Case Studies | 3 (8.57%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (40.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Nuclear Factor-kappa B (NFkB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia (AML) [NCT00156299] | Phase 1 | 15 participants (Actual) | Interventional | 2003-03-31 | Terminated(stopped due to Replaced by another study) | ||
| A Randomized Phase II Study of Nuclear Factor-kappa B (NF-κB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia [NCT02144675] | Phase 2 | 27 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Phase II Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) Plus Dexamethasone & Choline Magnesium Trisalicylate in the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia [NCT01009931] | Phase 2 | 1 participants (Actual) | Interventional | 2011-03-31 | Terminated(stopped due to Study was terminated early due to lack of experimental medication (supply issues)) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||